Adonis vs Claimable
Two Denials & Appeals vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Adonis | Claimable | |
|---|---|---|
| Pricing model | Not published · Custom quotes via demo | Per-transaction / per-chart · about $40-50 per appeal, some free |
| Speed to go live | API connection to EHR, billing, payer portals | consumer self-serve, appeal drafted in minutes |
| Automation model | Autonomous agents · agents plus revenue intelligence alerts | AI copilot · drafts evidence-backed appeal letters |
| Built for | Mid-size groups, Enterprise systems, Billing companies | Small practices, Enterprise systems |
| Security posture | HIPAA | SOC 2 Type II, HIPAA |
| Company maturity | 4 yrs (est. 2022) | 3 yrs (est. 2023) |
| Financial backing | $95M+ · Series C | $10M · Seed |
| Named customers | 5 named | None public |
| Published results | No public numbers | Specific numbers public |
| Documented integrations | 5 listed | None documented |
| Third-party validation | None found | None found |
Bottom line
- Pick Adonis if you want AI agents and revenue analytics layered onto your existing EHR and billing stack without replacing it.
- Pick Claimable if patients or one-off denials need fast, cheap, evidence-backed appeals with zero procurement.
Adonis
Revenue intelligence and denial prevention
- Founded
- 2022
- HQ
- New York, NY
- Stage
- Series C
- Raised
- $95M+
What it does
- Real-time revenue intelligence dashboards across the claim lifecycle
- Detects denials, underpayments, and revenue leakage automatically
- AI agents work claims: status checks, appeals, resubmissions
- Prioritized worklists route staff to highest-value tasks
- Alerts on payer behavior changes before revenue impact spreads
- Orchestration layer sits on top of existing billing systems
Where it's strong
- Analytics-first approach surfaces why revenue is leaking, not just that it is, which most billing systems cannot do.
- AI agents now autonomously progress claims, and traction is real: 4x revenue growth in 2025 with Mount Sinai as a flagship customer.
- Works on top of your existing EHR and billing stack rather than replacing it.
What buyers should weigh
- It augments your RCM team rather than replacing it; you still need billers, unlike full-service RCM vendors.
- The company is four years old and scaling fast, so expect some product churn and evolving packaging.
- Value depends on claim volume; small practices may not generate enough data to justify the platform.
Named customers
Mount Sinai Health System · Allied Digestive Health · ApolloMD · Seaview Orthopaedic & Medical Associates · Tend Dental
Integrations
Claimable
AI-generated appeals for denied health insurance claims
- Founded
- 2023
- HQ
- Sacramento, CA
- Stage
- Seed
- Raised
- $10M
What it does
- AI-drafted appeals citing policy terms and medical literature
- Delivery to insurer appeals departments and executives
- Coverage for 28 conditions and 90+ treatments
- Support for 80+ medications including Humira and Dupixent
- Case tracking with most resolved within 10 days
Where it's strong
- Reports roughly 75 to 80% of appeals ending in overturned denials, far above typical patient appeal rates.
- Flat per-case pricing around $50 makes it accessible without a contract or implementation.
- Founding team combines clinical, payer, and VA data science backgrounds, and the escalation tactic of copying executives and regulators gets responses.
What buyers should weigh
- Coverage is limited to a defined list of conditions and treatments, so many denial types are out of scope today.
- The core product is patient-facing; provider and enterprise offerings are newer and less proven at volume.
- It appeals one claim at a time and does not address the upstream documentation or authorization issues driving denials.
Compare against the rest of Denials & Appeals
Deciding between these two?
First Pass tracks Denials & Appeals every week: funding, launches, and what changed since this page was written.